{
    "Clinical Trial ID": "NCT00354640",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Anastrozole and Simvastatin",
        "  adjuvant therapy : laboratory analysis",
        "  pharmacological study : laboratory analysis",
        "  simvastatin : 40 milligram tablet PO QD for 14 days",
        "  anastrozole : 1 milligram tablet PO QD for 14 days"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Meets any of the following criteria:",
        "  History of invasive breast cancer",
        "  History of ductal carcinoma in situ",
        "  At high risk for breast cancer, defined as being on anastrozole for chemoprevention of breast cancer",
        "  Receiving anastrozole for  30 days as adjuvant breast cancer treatment or for prevention of breast cancer",
        "  No active breast cancer with known metastatic involvement",
        "  Hormone receptor status not specified",
        "  PATIENT CHARACTERISTICS:",
        "  Female",
        "  Postmenopausal",
        "  ECOG performance status 0-2",
        "  AST and ALT  3 times upper limit of normal",
        "  Creatinine clearance  30 mL/min",
        "  No active liver disease",
        "  No prior hypersensitivity to any HMG-CoA reductase inhibitor or any of its components",
        "  No daily alcohol use of > 3 standard drinks/day",
        "  A standard drink is defined as 10 g of alcohol, which is equivalent to 285 mL of beer, 530 mL of light beer, 100 mL of wine, or 30 mL of liquor",
        "  PRIOR CONCURRENT THERAPY:",
        "  See Disease Characteristics",
        "  No cholesterol-lowering drug, including a statin, within the past 3 months",
        "  No selective estrogen receptor modulator (SERM) within the past 3 months",
        "  No other hormone therapy within the past 3 months",
        "  No prior estrogen and/or progesterone hormone replacement therapy that lasted for  5 years",
        "  Vaginal estrogen preparations allowed",
        "  No other concurrent statin or cholesterol-lowering drug",
        "  No other concurrent SERM",
        "  No other concurrent hormone therapy",
        "  No other concurrent investigational drugs",
        "  No concurrent CYP3A4 inhibitors, including itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, or cyclosporine",
        "  No concurrent chemotherapy or biological agents",
        "  No concurrent daily grapefruit juice > 8 oz/day",
        "  No other concurrent anticancer agents or therapies"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Change in Blood Concentrations",
        "  The change in blood concentrations of anastrozole at baseline and 14 days was measured.",
        "  Time frame: Baseline and 14 days",
        "Results 1: ",
        "  Arm/Group Title: Anastrozole and Simvastatin",
        "  Arm/Group Description: adjuvant therapy : laboratory analysis",
        "  pharmacological study : laboratory analysis",
        "  simvastatin : 40 milligram tablet PO QD for 14 days",
        "  anastrozole : 1 milligram tablet PO QD for 14 days",
        "  Overall Number of Participants Analyzed: 9",
        "  Median (Full Range)",
        "  Unit of Measure: ng/ml  Anastrozole concentration: 4.2        (-6.2 to 22.1)",
        "  Hydroxyanastrozole concentration: -0.03        (-0.14 to 0.08)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/11 (0.00%)"
    ]
}